FDA Advisory Panel Recommends Easing Restrictions on Unapproved Peptides Despite Agency Scientists' Concerns

Jul 24, 2026

An FDA advisory panel voted to recommend easing compounding restrictions on six unapproved peptides, including BPC-157 and Semax, while rejecting emideltide. The decision, which reverses Biden-era restrictions, represents a major victory for Health Secretary Robert F. Kennedy Jr. and the wellness industry. However, the vote drew sharp criticism from FDA staff scientists who warned of a lack of clinical safety data, amid concerns over the panel's newly appointed members who have extensive ties to the peptide industry.

FDA advisory panel peptide recommendations

▪The Food and Drug Administration Pharmacy Compounding Advisory Committee voted to recommend that compounding pharmacies be allowed to manufacture six out of seven unapproved peptides under review.
▪The Food and Drug Administration Pharmacy Compounding Advisory Committee recommendations are non-binding, and the Food and Drug Administration will make the final decision through a formal rulemaking process.
▪The Food and Drug Administration Pharmacy Compounding Advisory Committee voted to recommend compounding for BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax, while voting against emideltide.

Insufficient clinical trial evidence

▪Dr. Rachel Pessah-Pollack stated that the peptide BPC-157 has only been tested in approximately 30 humans, compared to the hundreds of thousands of patients involved in GLP-1 clinical trials.
▪Food and Drug Administration official Russell Wesdyk stated that the chemical composition of peptides labeled with the same name varies considerably, presenting a foundational challenge for establishing quality standards.
▪Food and Drug Administration staff scientists opposed loosening restrictions, stating there is a lack of clinical trial data to establish the safety and effectiveness of the reviewed peptides.

Panel members' industry connections

▪Health and Human Services Secretary Robert F. Kennedy Jr., who has publicly supported peptide therapies, appointed the new panel members who voted to ease the peptide compounding restrictions.
▪Committee member Tennessee State Senator Bobby Harshbarger is the son of Representative Diana Harshbarger, who previously requested that compounding pharmacies be allowed to manufacture certain peptides.
▪Prior to the meeting, the Department of Health and Human Services appointed eight new members to the 14-member advisory committee, most of whom have ties to the peptide industry.

Compounding pharmacy regulatory pathway

▪During the Biden administration, the Food and Drug Administration added nearly 20 peptides to a federal list of substances barred from legal compounding due to safety risks.
▪If the Food and Drug Administration approves the compounding of the six peptides, patients will require a doctor's prescription to obtain the therapies from specialized compounding pharmacies.

Unregulated online peptide sales

▪Medical experts warn that gray market peptides purchased online carry significant risks of contamination, impurities, infections, or allergic reactions.
▪Unapproved peptides are widely sold online in a 'gray market' under labels such as 'for research use only' and 'not for human consumption' to bypass federal drug regulations.